- In November 2022, Anika Therapeutics Inc., a prominent company specializing in joint preservation healthcare, successfully completed a phase-3 clinical trial focused on a single primary endpoint. This medication is specifically designed for individuals suffering from severe knee osteoarthritis. The company is now concentrating on obtaining FDA approval for its treatment and seeking clearance for use in the global market
- In June 2022, Johnson and Johnson released new findings from phase-3 trials demonstrating that patients treated with their medications experienced better and more consistent long-term outcomes over two years while managing active psoriatic arthritis
- In May 2022, Fidia Farmaceutici SPA successfully leveraged the regenerative properties of hyaluronic acid (HA) through its innovative product portfolio, which was introduced in Spain. This portfolio aims to enhance tissue repair and promote healing in various medical applications. By harnessing the unique benefits of HA, Fidia is positioning itself as a leader in the regenerative medicine market
- In April 2022, Kolen Life entered into a partnership with Juniper Biologics to develop and commercialize TissueGene-C low dose, an innovative therapy for knee osteoarthritis. This treatment is delivered as a single intra-articular injection and does not necessitate surgical intervention
- In May 2021, Ono Pharmaceutical Co., Ltd. and Seikagaku Corporation introduced JOYCLU, a 30mg intra-articular injection designed to enhance joint function. Seikagaku received manufacturing and marketing approval for this product in Japan in March 2021
Frequently Asked Questions
The market is segmented based on Segmentation, By Source (Animal Origin And Non-Animal Origin), Age Group (Geriatric And Adults), Injection (Single Injection, Three Injections, and Five Injections), Molecular Weight (Intermediate Molecular Weight, Low Molecular Weight, and High Molecular Weight), End User (Hospital, Orthopedic Clinics, Ambulatory Care Centers, and Others), Distribution Channel (Direct Tender And Retail Sales) – Industry Trends and Forecast to 2031
.
The Global Viscosupplementation Market size was valued at USD 1.53 USD Billion in 2023.
The Global Viscosupplementation Market is projected to grow at a CAGR of 8.5% during the forecast period of 2024 to 2031.
The major players operating in the market include Anika Therapeutics , SEIKAGAKU CORPORATION, Bioventus, Fidia Farmaceutici S.P.A, Ferring B.V, sanofi-aventis U.S. LLC, Zimmer Biomet, OrthogenRx , APTISSEN, Johnson & Johnson Services , LG Chem, Viatris , and others.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
